Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 4 Neoplasm Metastasis 2 Melanoma 2 Breast Neoplasms 2 Brain Neoplasms 2 Thyroid Cancer, Papillary 1 Solid Tumors 1 Sarcoma 1 Salivary Gland Neoplasms 1 Rare Tumour 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Noonan Syndrome 6 1 Neuroendocrine Tumors 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Lymphoma, Large-Cell, Anaplastic 1 Locally Advanced Thyroid Gland Carcinoma 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Glioma 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Lobular 1 Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Carboplatin 4 Trastuzumab 3 Cyclophosphamide 3 Paclitaxel 2 Letrozole 2 Fulvestrant 2 Docetaxel 2 repotrectinib 1 proto-oncogene protein c-fes-fps 1 palbociclib 1 neratinib 1 entrectinib 1 Vorinostat 1 Vinorelbine 1 Thiotepa 1 Taxes 1 Tamoxifen 1 Sugars 1 Radiotherapy 1 Positron Emission Tomography Computed Tomography 1 Neoadjuvant Therapy 1 Naltrexone 1 Melphalan 1 Mastectomy, Segmental 1 Magnetic Resonance Spectroscopy 1 Liquid Biopsy 1 High-Energy Shock Waves 1 Goserelin 1 Fluorine-18 1 Epirubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Lobular × entrectinib × Clear all

NCT04551495 2024-12-04

ROSALINE

Jules Bordet Institute

Phase 2 Unknown

Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡